US Telehealth Deal Volume Drops 10% as M&A Consolidates Virtual Care and Pharmacy

Deal Volume Decline Signals Market Maturation

US telemedicine fundraising activity dropped from 146 deals in 2023 to 131 in 2024, according to Drake Star's Q1 2025 Telemedicine Report tracking global M&A and capital activity from 2015 through Q1 2025. Europe showed sharper deceleration: 58 fundraisings in 2023 fell to 35 in 2024. Through Q1 2025, the US recorded 19 deals versus 5 in Europe. The report's thesis: M&A is increasing while new entrants decline, marking a consolidating market where platform buyers face fewer standalone vendors and more integrated stack providers.

The US captured over 2,472 telemedicine-related transactions (M&A plus fundraising) between 2015 and 2024. The five most active European countries combined registered 894 deals over the same period. This concentration means enterprise telehealth buyers in North America operate in a vendor landscape shaped by serial acquirers, not a fragmented field of independent platforms.

Key Acquisitions Redraw the Vendor Map

Six 2024 acquisitions redefine which companies control virtual care, pharmacy fulfillment, and AI-enabled remote monitoring:

- Stryker acquired care.ai, an AI patient-monitoring platform deployed by Ecumen and Signature Healthcare. This moves virtual rounding and AI surveillance into Stryker's medical device ecosystem. - Avel eCare acquired Amwell's psychiatric services assets, consolidating telepsychiatry under a specialist operator. - LetsGetChecked acquired Truepill, combining at-home diagnostics with digital pharmacy and patient monitoring in a single platform. - Paulus Holdings acquired Alto, the digital pharmacy, and Scriptology acquired RxLive, the telehealth clinical pharmacy provider, tying prescription fulfillment directly to virtual consultations. - Treatment AI acquired innovaTel, a telepsychiatry provider, adding clinical delivery to an AI-first company.

These transactions bundle telehealth, pharmacy, and remote monitoring into vertically integrated offerings. Health systems and payers that built telehealth stacks from best-of-breed point products now face competitors selling end-to-end virtual care plus fulfillment under one contract. Platforms like Teladoc and remaining standalone Amwell assets compete against vendors that own the prescription and the device layer, not just the video visit.

Vendor Risk and Contract Structure

With over 2,472 US deals completed and M&A accelerating, enterprise buyers should treat vendor stability as a variable, not a constant. RFPs must include FHIR and HL7 API requirements, explicit data portability clauses, and change-of-control protections. A telehealth platform acquired mid-contract may shift from independent SaaS to a bundled offering inside a medical device or pharmacy parent, changing pricing, support structure, and product roadmap.

Buyers standardizing on a single platform should model integration and re-platforming costs if the vendor is acquired within a 3-to-5-year contract term. The Amwell psychiatric assets moving to Avel eCare and care.ai entering Stryker's portfolio illustrate how clinical workflows, user interfaces, and vendor relationships change post-acquisition.

Total Cost of Ownership Shifts Toward Bundles

Consolidations like Scriptology-RxLive and LetsGetChecked-Truepill enable virtual care, pharmacy fulfillment, and remote monitoring to be priced as integrated per-encounter or per-member-per-month packages. Buyers stitching together separate telehealth, pharmacy, and monitoring vendors face higher integration costs and more vendor relationships. A consolidated platform may carry a higher license fee but lower total spend on APIs, support contracts, and interoperability engineering.

Enterprises heavily invested in Stryker hardware should expect tighter device-software bundles following the care.ai acquisition. Budgets previously allocated to standalone SaaS telemonitoring products may shift to device-linked platforms with AI-enabled virtual rounding embedded in capital equipment contracts.

Market Growth Supports Multi-Year Platform Commitments

Vantage Market Research forecasts the global telehealth market will grow from $94.6 billion in 2025 to $412.3 billion by 2035, a 15.9% compound annual growth rate. This revenue headroom reduces near-term existential risk for leading platforms and justifies continued R&D in AI, remote monitoring, and hybrid care models. CIOs can defend multi-year telehealth platform investments as growth budget lines, not temporary COVID-era add-ons.

The growth trajectory supports 3-to-5-year enterprise commitments if the platform roadmap aligns with AI-driven remote monitoring and integrated pharmacy fulfillment. A market expanding from roughly $95 billion to over $400 billion in ten years provides vendor stability and product development capital, making long-term contracts less risky than in a flat or declining category.

What to Watch

Track which platforms raise capital in 2025 and which are acquired. Fundraising in Q1 2025 included remote consultation platforms jrnys and Rula, healthcare integration software Rhapsody, patient-monitoring platforms CoachCare and Healthie, and telehealth emergency care platform MD Ally. Companies that skip fundraising rounds and go directly to acquisition talks signal distress or strategic repositioning.

Monitor how Stryker integrates care.ai's AI surveillance and virtual rounding into device sales cycles. If AI-enabled monitoring becomes a standard feature in Stryker hardware contracts, standalone telemonitoring vendors lose differentiation. Health systems standardized on competing device platforms (Philips, GE HealthCare) should evaluate whether their current telemonitoring vendors can match AI capabilities or if they need to switch to keep pace.